Former committee member at Edwards Lifesciences Corp
- Key trends and developments in the cardiovascular device industry, focusing on Edwards Lifesciences (NYSE: EW)
- TAVR (transcatheter aortic valve replacement) market opportunity, growth runway and Edwards’ penetration prospects
- Edwards’ expansion into the TMTT (transcatheter mitral and tricuspid therapies) sector and ability to compete with first-mover Abbott Laboratories (NYSE: ABT)
- International landscape, including headwinds in China market
- 2022 outlook – anticipated R&D efforts and potential consolidation
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.